Clinical trials: Induction Chemotherapy
Chemotherapy-induced Nausea and Vomiting
Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)
The purpose of this study was to determine the appropriate dosing regimen of fosaprepitant, when administered with ondansetron (with or without dexamethasone), for the prevention of CINV in children from birth to <17 years of…
- Trial name
- NCT01697579
- Testing
- Fosaprepitant, Ondansetron, 5-hydroxytryptamine 3 antagonist
- Volunteers
- 240 people
- Sponsor
- Merck Sharp & Dohme LLC
Oral Mucositis
Study to Assess Safety and Tolerability of AG013 in Oral Mucositis in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck
The purpose of this study is to assess the safety and tolerability of AG013 (genetically modified L. lactis bacteria engineered to secrete human Trefoil Factor 1), and to explore the ability of AG013 to attenuate the course and…
- Trial name
- NCT00938080
- Testing
- AG013
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- ActoGeniX N.V.
Diabetic Neuropathy, Chemotherapy Induced Neuropathy
A Clinical Outcomes Study to Measure Reduction in Pain and Numbness During Administration of an Amino Acid Formulation in Subjects Diagnosed With Peripheral Neuropathy
A clinical outcomes study measuring reduction in pain and numbness experienced in four types of peripheral neuropathy patients during 60 day administration of the an amino acid formulation.
- Conditions
- Diabetic Neuropathy, Chemotherapy Induced Neuropathy, HIV Neuropathy, Trauma Induced Neuropathy
- Trial name
- Neuron012703 (NCT01537705)
- Testing
- Neuron012703 (Medical Food)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Targeted Medical Pharma
Newly Diagnosed FLT3 Mutated AML
Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML
A phase III randomized multi-center study designed to compare the efficacy of crenolanib with that of midostaurin when administered following induction chemotherapy, consolidation chemotherapy and bone marrow transplantation in…
- Trial name
- NCT03258931
- Testing
- Crenolanib, Midostaurin, Cytarabine
- Where
- 31 sites in United States
- Volunteers
- 214 people
- Sponsor
- Arog Pharmaceuticals, Inc.
Chemotherapy-Induced Nausea and Vomiting
Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)
The study will test aprepitant for the prevention of CINV in patients receiving their initial cycle of Moderately Emetogenic Chemotherapy (MEC).
- Trial name
- NCT00337727
- Testing
- aprepitant, Comparator: ondansetron, Comparator: dexamethasone
- Volunteers
- 848 people
- Sponsor
- Merck Sharp & Dohme LLC
Extensive-stage Small-cell Lung Cancer
Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world Study
This is a single-arm, real-world study in Chinese patients with extensive stage small cell lung cancer. The purpose of this study was to evaluate Trilaciclib's protection against chemotherapy-induced bone marrow suppression, the…
- Trial name
- NCT05071703
- Testing
- Trilaciclib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Chemotherapy-induced Peripheral Neuropathy
Study of SIR2501 in Solid Tumor Patients Receiving Paclitaxel
This Phase 2, open-label study will evaluate the safety, tolerability, and pharmacokinetics of SIR2501 in adults with solid tumors who are scheduled to receive paclitaxel-based chemotherapy.
- Trial name
- NCT07765446
- Testing
- SIR2501
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Sironax USA, Inc.
Chemotherapy-induced Nausea and Vomiting (CINV)
Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)
This study will demonstrate and confirm the efficacy and safety of MK0869 for the treatment of chemotherapy-induced nausea and vomiting in Chinese patients.
- Trial name
- NCT00952341
- Testing
- aprepitant, dexamethasone, granisetron
- Volunteers
- 421 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy Induced Nausea and Vomiting
A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)
This study will compare the safety and efficacy of a three-day oral aprepitant regimen (aprepitant plus ondansetron) to ondansetron alone in the prevention of chemotherapy-induced nausea and vomiting (CINV) in the 120 hours…
- Trial name
- NCT01362530
- Testing
- Aprepitant 125 mg, Aprepitant 80 mg, Aprepitant powder for suspension (PFS)
- Volunteers
- 307 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy-Induced Myelosuppression
Careseng 1370 for Chemotherapy-Induced Myelosuppression
This is a Phase I/IIa dose-finding (Phase I) followed by randomized, double-blind, placebo-controlled, parallel, add-on to cisplatin + docetaxel (Phase IIa) study to evaluate the safety, tolerability, and efficacy profiles of…
- Trial name
- NCT03692780
- Testing
- Careseng 1370
- Sponsor
- Careseng Biotech Co., Ltd.
Nausea, Vomiting
Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030)
This study will assess the efficacy of a single dose of intravenous (IV) fosaprepitant (MK-0517, EMEND® IV) as salvage therapy when added to a 5-hydroxytryptamine receptor 3 antagonist (5-HT3 RA) and dexamethasone for the…
- Trial name
- EVADE (NCT01405924)
- Testing
- Fosaprepitant dimeglumine, 5-HT3 RA, Dexamethasone
- Volunteers
- 111 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy-Induced Thrombocytopenia
A Study of the Safety and Efficacy of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia
The primary objective of this study is to evaluate the safety and tolerability of ONO-7746 across multiple doses in patients with solid tumors and chemotherapy induced thrombocytopenia (CIT) scheduled to receive at least two…
- Trial name
- NCT01345214
- Testing
- ONO-7746
- Where
- 14 sites in United States, Russia and 1 more
- Volunteers
- 17 people
- Sponsor
- Ono Pharma USA Inc
Colorectal Cancer Metastatic, Myelosuppression-Adult
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):
This was a randomized, double-blind, placebo-controlled, global, multicenter, Phase 3 trial evaluating the impact of trilaciclib on myelopreservation and anti-tumor efficacy when administered prior to FOLFOXIRI/bevacizumab in…
- Conditions
- Colorectal Cancer Metastatic, Myelosuppression-Adult, Chemotherapeutic Toxicity
- Trial name
- PRESERVE1 (NCT04607668)
- Testing
- Trilaciclib
- Where
- 82 sites in United States, China and 6 more
- Volunteers
- 326 people
- Sponsor
- G1 Therapeutics, Inc.
Chemotherapy-induced Nausea and Vomiting
To Study the Safety and Effectiveness of a Granisetron Patch to Treat Chemotherapy-Induced Nausea and Vomiting (CINV)
To study the safety and effectiveness of a granisetron patch to treat Chemotherapy-Induced Nausea and Vomiting (CINV)
- Trial name
- NCT00273468
- Testing
- Granisetron
- Volunteers
- 630 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Chemotherapy-induced Peripheral Neuropathy, Chemotherapy-induced Neuropathic Pain
Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN)
Peripheral neuropathy is a disorder caused by damage to the peripheral nerves. Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of certain chemotherapy drugs, such as platinum-based compounds, taxanes…
- Conditions
- Chemotherapy-induced Peripheral Neuropathy, Chemotherapy-induced Neuropathic Pain, CIPN - Chemotherapy-Induced Peripheral Neuropathy, Peripheral Neuropathic Pain
- Trial name
- NCT07072468
- Testing
- VMD-3866 Gel
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- VM Therapeutics LLC
Chemotherapy-induced Nausea and Vomiting
Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)
MyRisk: Efficacy and safety evaluation of oral Akynzeo® in patients receiving MEC at high risk of developing CINV based on a prediction tool. A multinational and multicenter study.
- Trial name
- CINV (NCT04817189)
- Testing
- NEPA (300mg netupitant/0.5mg palonosetron), Granisetron, 2 mg (oral) or 1 mg (IV) OR Palonosetron, 0.5 mg (oral), 0.25mg (IV) OR Ondansetron, 16 mg (oral) or 8 mg (IV) OR Dolasetron 100 mg (oral) OR Tropisetron 5 mg (oral or IV), Dexamethasone, 8 mg (oral) or equivalent IV dose
- Where
- 19 sites in China, Czechia and 5 more
- Volunteers
- 414 people
- Sponsor
- Helsinn Healthcare SA
Oncology Pain, Chemotherapy-induced Peripheral Neuropathy
The Potential Protective Role of Venlafaxine Versus Memantine in Paclitaxel Induced Peripheral Neuropathy
This is a double blinded two-arm randomized case-only interventional trial. A total of 60 patients who are to receive Paclitaxel to be included and allocated in two groups.
- Trial name
- NCT04737967
- Testing
- Venlafaxine, Memantine
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Mendel AI
Chemotherapy-induced Peripheral Neuropathy
Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients
To evaluate the safety and tolerability of ART-123 in patients with metastatic colorectal cancer who receive oxaliplatin-containing chemotherapy and bevacizumab
- Trial name
- NCT05251727
- Testing
- thrombomodulin alfa
- Where
- 32 sites in United States, Japan
- Volunteers
- 77 people
- Sponsor
- Veloxis Pharmaceuticals
Diarrhea
Proof-of-Concept Study in Cancer Patients to Assess Efficacy of Elsiglutide in Preventing Chemotherapy-Induced Diarrhea
The main objective of this study will be to obtain data on the efficacy of elsiglutide in preventing Chemotherapy Induced Diarrhea (CID) in patients with colorectal cancer receiving 5-FU based chemotherapy (FOLFOX4 or FOLFIRI…
- Trial name
- NCT01543451
- Testing
- Elsiglutide
- Where
- 21 sites in Bulgaria, Hungary and 2 more
- Volunteers
- 138 people
- Sponsor
- Helsinn Healthcare SA
Locally Advanced or Metastatic Breast Cancer
Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy
Study E7389-M044-504 is an observational, post-authorization, single-arm, prospective, multicenter cohort study conducted to characterize and determine the incidence of eribulin-induced peripheral neuropathy (PN), and the…
- Trial name
- IRENE (NCT03027245)
- Testing
- Eribulin
- Where
- 65 sites in Germany
- Volunteers
- 353 people
- Sponsor
- Eisai GmbH